Your fact-checks will appear here
Review of liver-specific safety of ivermectin
High‑dose ivermectin studies in humans and pharmacovigilance analyses document a spectrum of neurologic events—from common, mild symptoms such as dizziness and somnolence observed in trials to rare bu...
The human body clears ivermectin mainly through metabolism and fecal excretion, with a plasma half-life of roughly 18 hours and metabolites that can persist longer — some reported at ~55 hours — so el...
No completed or registered human clinical trials testing ivermectin specifically as a therapy for liver fibrosis or nonalcoholic fatty liver disease (NAFLD) are identified in the provided reporting; t...